Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1
Brief Summary: This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG) + Ribavirin (RBV) (weight-based dosing \[WBD\]) in previously untreated adult participants with chronic hepatitis C (CHC) genotype 1. It is hypothesized that the addition of a third active anti- Hepatitis C Virus (anti-HCV) drug may lead to more rapid viral response than therapy with two drugs, and therefore, the addition of boceprevir to PegIntron plus ribavirin therapy after a 4-week lead-in period may allow for both increased rates of sustained virologic response (SVR) and shorter treatment durations (in some populations) than treatment with PegIntron plus ribavirin alone.

The study includes two separate cohorts, Cohort I (White participants) and Cohort II (Black participants). Participants from each cohort are assigned (randomized) to one of three study arms, all of which have a 4-week lead-in period with (PEG + RBV).


Options:
A: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
C: Arm Label: TMC435/PR; Type: EXPERIMENTAL; Interventions: Drug: TMC435 | Arm Label: TVR/PR; Type: ACTIVE_COMPARATOR; Interventions: Drug: TVR | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435/PR | Intervention Type: DRUG; Name: TVR; Assigned to Arm(s): TVR/PR
D: Arm Label: Sofosbuvir+PEG+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Sofosbuvir+PEG+RBV

Answer: A